JP2021510702A5 - - Google Patents

Info

Publication number
JP2021510702A5
JP2021510702A5 JP2020538844A JP2020538844A JP2021510702A5 JP 2021510702 A5 JP2021510702 A5 JP 2021510702A5 JP 2020538844 A JP2020538844 A JP 2020538844A JP 2020538844 A JP2020538844 A JP 2020538844A JP 2021510702 A5 JP2021510702 A5 JP 2021510702A5
Authority
JP
Japan
Prior art keywords
inhibitor
product according
conjugate
pharmaceutical product
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020538844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510702A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/013314 external-priority patent/WO2019140271A2/en
Publication of JP2021510702A publication Critical patent/JP2021510702A/ja
Publication of JP2021510702A5 publication Critical patent/JP2021510702A5/ja
Priority to JP2023186470A priority Critical patent/JP7703001B2/ja
Pending legal-status Critical Current

Links

JP2020538844A 2018-01-12 2019-01-11 相乗的がん治療 Pending JP2021510702A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023186470A JP7703001B2 (ja) 2018-01-12 2023-10-31 相乗的がん治療

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201862617095P 2018-01-12 2018-01-12
US62/617,095 2018-01-12
US201862674483P 2018-05-21 2018-05-21
US62/674,483 2018-05-21
US201862700147P 2018-07-18 2018-07-18
US62/700,147 2018-07-18
US201862711423P 2018-07-27 2018-07-27
US201862711421P 2018-07-27 2018-07-27
US62/711,421 2018-07-27
US62/711,423 2018-07-27
US201862716796P 2018-08-09 2018-08-09
US201862716788P 2018-08-09 2018-08-09
US62/716,796 2018-08-09
US62/716,788 2018-08-09
PCT/US2019/013314 WO2019140271A2 (en) 2018-01-12 2019-01-11 Synergistic cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023186470A Division JP7703001B2 (ja) 2018-01-12 2023-10-31 相乗的がん治療

Publications (2)

Publication Number Publication Date
JP2021510702A JP2021510702A (ja) 2021-04-30
JP2021510702A5 true JP2021510702A5 (cg-RX-API-DMAC7.html) 2022-01-19

Family

ID=67218383

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020538844A Pending JP2021510702A (ja) 2018-01-12 2019-01-11 相乗的がん治療
JP2020538819A Pending JP2021510701A (ja) 2018-01-12 2019-01-11 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤
JP2023186470A Active JP7703001B2 (ja) 2018-01-12 2023-10-31 相乗的がん治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020538819A Pending JP2021510701A (ja) 2018-01-12 2019-01-11 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤
JP2023186470A Active JP7703001B2 (ja) 2018-01-12 2023-10-31 相乗的がん治療

Country Status (10)

Country Link
US (4) US11730836B2 (cg-RX-API-DMAC7.html)
EP (2) EP3737383A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021510702A (cg-RX-API-DMAC7.html)
KR (2) KR20200110377A (cg-RX-API-DMAC7.html)
CN (2) CN111587115A (cg-RX-API-DMAC7.html)
AU (2) AU2019206623A1 (cg-RX-API-DMAC7.html)
CA (2) CA3087628A1 (cg-RX-API-DMAC7.html)
MX (3) MX2020007442A (cg-RX-API-DMAC7.html)
RU (1) RU2020126774A (cg-RX-API-DMAC7.html)
WO (2) WO2019140271A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020219943A1 (en) 2019-04-26 2020-10-29 Prolynx Llc Slow-release cytokine conjugates
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
US12472261B2 (en) 2019-08-28 2025-11-18 Prolynx Llc Conjugated inhibitors of DNA damage response
CN119213060A (zh) * 2022-04-14 2024-12-27 国立研究开发法人量子科学技术研究开发机构 单一高分子颗粒、活性分子复合物、单一高分子颗粒的制造方法、肿瘤尺寸的计测方法、肿瘤内微细结构的计测方法、生物体组织的成像方法、药物递送体系、造影剂试剂盒
US20260034120A1 (en) * 2022-08-04 2026-02-05 Prolynx Llc Treating cancer with long-acting topoisomerase i inhibitor
WO2024030998A2 (en) * 2022-08-04 2024-02-08 Prolynx Llc Methods of treating cancer with long-acting topoisomerase i inhibitor

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2319854B1 (en) 1997-01-08 2016-11-30 Sigma-Aldrich Co. LLC Bioconjugation Of Macromolecules
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
AU2003253890A1 (en) 2002-07-12 2004-02-02 Biomarin Pharmaceutical Inc. The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
CA2502870C (en) 2002-10-31 2011-07-26 Nippon Kayaku Kabushiki Kaisha High-molecular weight derivatives of camptothecins
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
CN1852740B (zh) 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
MX2009002855A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales.
EP2307032A4 (en) * 2008-05-22 2014-08-20 Univ Ramot NEW CONJUGATES OF POLYMERS WITH A THERAPEUTIC AGENT AND AN ANGIOGENESIS TARGETING PART CONTAINED THEREOF, AND USES IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS
CN102076331B (zh) 2008-06-26 2013-12-18 普罗林科斯有限责任公司 具有可控的药物释放速率的前药和药物-大分子轭合物
US20100098654A1 (en) 2008-10-21 2010-04-22 Fabio Pastorino Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
EP2366105A1 (en) 2008-11-18 2011-09-21 Baxter International Inc. Methods of determining polydispersity and/or molecular weight distribution of a polyethylene glycol sample
JP2012528240A (ja) 2009-05-28 2012-11-12 メルサナ セラピューティックス, インコーポレイテッド 可変速度放出リンカーを含むポリアル−薬物コンジュゲート
CA2780645C (en) * 2009-11-18 2018-01-16 Nektar Therapeutics Salt form of a multi-arm polymer-drug conjugate
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
WO2011140376A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from dendrimers
TW201215412A (en) 2010-08-30 2012-04-16 Sun Pharma Advanced Res Co Ltd Stable pharmaceutical composition
CN108721284A (zh) * 2010-11-16 2018-11-02 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合
WO2012088282A1 (en) 2010-12-21 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
IN2014MN01819A (cg-RX-API-DMAC7.html) 2012-03-05 2015-07-03 Univ Ramot
TWI486341B (zh) * 2012-05-18 2015-06-01 高雄醫學大學 抑制atr與fancd2激活之組成物與方法
WO2014194289A1 (en) * 2013-05-31 2014-12-04 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents
CN106061483B (zh) * 2013-10-04 2021-01-08 普洛林克斯有限责任公司 Sn-38的缓释结合物
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015118338A1 (en) * 2014-02-07 2015-08-13 Mission Therapeutics Limited Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways
US20150343100A1 (en) * 2014-05-28 2015-12-03 Memorial Sloan Kettering Cancer Center Bimodal fluorophore-labeled liposomes and associated methods and systems
EP3180031A1 (en) * 2014-08-13 2017-06-21 The Johns Hopkins University Selective dendrimer delivery to brain tumors
WO2016028636A1 (en) 2014-08-16 2016-02-25 Memorial Sloan Kettering Cancer Center Helical polycarbodiimide polymers and associated imaging, diagnostic, and therapeutic methods
JP6378584B2 (ja) 2014-08-29 2018-08-22 キヤノン株式会社 通信システム、画像処理装置、画像処理装置の制御方法、及びプログラム
US10196412B2 (en) * 2014-12-24 2019-02-05 The Board Of Trustees Of The Leland Stanford Junior University Probe for imaging PARP-1 activity
PL3277681T3 (pl) 2015-04-02 2019-10-31 Merck Patent Gmbh Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm
HK1250646A1 (zh) * 2015-04-07 2019-01-11 Memorial Sloan Kettering Cancer Center 纳米粒子免疫偶联物
US10973925B2 (en) * 2015-04-28 2021-04-13 University Of Central Florida Research Foundation Inc. Methods and compositions for theranostic nanoparticles
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
US10821195B2 (en) 2015-09-10 2020-11-03 Memorial Sloan Kettering Cancer Center Compositions for therapeutics, targeted PET imaging and methods of their use
US12048753B2 (en) 2015-10-01 2024-07-30 Whitehead Institute For Biomedical Research Labeling of antibodies
US11154538B2 (en) 2016-02-29 2021-10-26 Synta Pharmaceuticals Corporation Combination therapy for treatment of ovarian cancer
WO2017172678A1 (en) * 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
RU2725292C2 (ru) 2016-04-27 2020-06-30 Иммьюномедикс, Инк. Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
AU2017258415B2 (en) * 2016-04-29 2023-03-30 Cornell University Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors
CN106084005B (zh) * 2016-06-15 2020-02-14 广州军区广州总医院 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用
CN107050471A (zh) * 2016-12-27 2017-08-18 中国药科大学 基于富勒烯的靶向且具有快速清除特征的显像纳米探针及其制备方法和应用

Similar Documents

Publication Publication Date Title
Bonelli et al. Precision medicine in gastric cancer
Chen et al. Improving radiotherapy in cancer treatment: Promises and challenges
Aghajanian et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Begg et al. Strategies to improve radiotherapy with targeted drugs
Drost et al. Opportunities and hurdles in the treatment of BRCA1-related breast cancer
Mauclet et al. Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab
WO2014172376A3 (en) Markers of tumor cell response to anti-cancer therapy
JP2017519006A5 (cg-RX-API-DMAC7.html)
WO2010063011A3 (en) Methods for the treatment of infections and tumors
WO2012061683A3 (en) Methods for treating cancer
JP2012528890A5 (cg-RX-API-DMAC7.html)
JP2019508429A5 (cg-RX-API-DMAC7.html)
Arrighetti et al. Drug combinations with HDAC inhibitors in antitumor therapy
US20220288404A1 (en) Methods for applying tumor treating fields in combination with cancer treating therapeutics
Rotolo et al. Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach
Sandomenico et al. Bevacizumab in non small cell lung cancer: development, current status and issues
AU2020296087A1 (en) Patient selection for enhancement of anti-tumor immunity in cancer patients
Cutsem et al. The role of chemotherapy in the current treatment of gastric cancer
Dong et al. Advances in evidence‐based medicine for immunotherapy of non‐small cell lung cancer
Crinò et al. Present and future treatment of advanced non–small cell lung cancer
AU2017324860A1 (en) PD-1 specific aptamers
Folprecht Liver Metastases in Colorectal Cancer.
Voorhees et al. Final results of a phase 1 study of vorinostat, pegylated liposomal doxorubicin, and bortezomib in relapsed or refractory multiple myeloma
DiPasco et al. The thrombophilic state in cancer part II: cancer outcomes, occult malignancy, and cancer suppression
Karavasilis Small cell lung cancer: current and future strategies